The news of Baird maintaining an Outperform rating and raising the price target for Iovance Biotherapeutics (NASDAQ:IOVA) from $20 to $23 is positive for the stock. This indicates that the analyst has a bullish outlook on the company's performance and expects the stock price to rise in the short term. The relevance and importance are high as the news directly pertains to IOVA and is significant for investors. The confidence in the analysis is also high due to the clear and direct impact of the news on the stock.